About Agios pharmaceuticals
Agios Pharmaceuticals: A Pioneer in Innovative Therapies
Agios Pharmaceuticals is a biopharmaceutical company that has been dedicated to developing innovative therapies for patients with cancer and rare genetic diseases. Founded in 2008, Agios has become a leader in the field of cellular metabolism, which plays a critical role in the growth and survival of cancer cells.
At Agios, the focus is on putting patients first and following the science. The company's mission is to transform the lives of patients with serious diseases by discovering and developing novel medicines that target key metabolic pathways. With a team of world-class scientists and researchers, Agios has made significant progress towards this goal.
One of Agios' core strengths is its expertise in cellular metabolism. The company's scientists have discovered several key metabolic pathways that are essential for cancer cell growth and survival. By targeting these pathways with small molecule inhibitors, Agios has developed a portfolio of differentiated therapies that have shown promising results in clinical trials.
Another strength of Agios is its commitment to collaboration. The company works closely with academic institutions, research organizations, and other biopharmaceutical companies to advance scientific understanding and accelerate drug development. This collaborative approach has led to several successful partnerships, including collaborations with Celgene (now part of Bristol Myers Squibb) and CStone Pharmaceuticals.
Agios' values are rooted in integrity, innovation, teamwork, accountability, respect for individuals, patient focus, excellence through diversity & inclusion as well as environmental sustainability. These values guide every aspect of the company's operations from research & development to commercialization.
The success story at Agios began when it received FDA approval for its first product Idhifa® (enasidenib) tablets on August 1st 2017; an oral targeted therapy used for treating adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation detected by an FDA-approved test after at least one prior therapy; this was followed by Tibsovo® (ivosidenib), another oral targeted therapy used for treating adult patients who have relapsed or refractory AML with an IDH1 mutation detected by an FDA-approved test after at least one prior therapy which was approved on July 20th 2018; both drugs were approved under accelerated approval based on overall response rate (ORR) data from single-arm trials.
In addition to these two products already approved by FDA there are other promising candidates currently being developed such as mitapivat which targets pyruvate kinase deficiency -a rare genetic disease- among others like AG-270 targeting methylthioadenosine phosphorylase deficiency-associated tumors or AG-636 targeting hematologic malignancies among others still under investigation.
As part of its commitment to making a positive difference for patients through truly differentiated therapies; In September 2020 Bristol Myers Squibb announced their intention to acquire all outstanding shares not already owned by them at $225 per share representing approximately $5 billion total equity value acquisition expected close during Q4/2020 subject regulatory approvals among other customary closing conditions.
In conclusion:
Agios Pharmaceuticals stands out as a pioneer in innovative therapies thanks to their dedication towards putting patients first while following science backed up by their core strengths such as expertise in cellular metabolism coupled up with collaboration spirit leading them into successful partnerships while guided by strong values throughout their operations from R&D all way down into commercialization.
Their portfolio includes two products already approved under accelerated approval based on overall response rate data from single-arm trials plus other promising candidates currently being developed aimed at addressing unmet medical needs across various indications.
With Bristol Myers Squibb acquisition expected soon we can only expect more exciting developments coming out from this dynamic biopharmaceutical firm committed towards transforming lives positively through novel medicines discovery & development efforts!